Getting your player ready...
Broomfield-based Accera Inc., a biotechnology company focusing on therapies in central- nervous-system diseases, announced it has closed a Series C financing round of $35 million, led by Inventages Venture Capital SA.
Proceeds of this financing will be used to begin sales and marketing of the company’s lead product, Axona (previously known as Ketasyn), which is scheduled to launch in the U.S. in the first quarter of 2009.
